Related references
Note: Only part of the references are listed.Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments
Michael Schotsaert et al.
EXPERT REVIEW OF VACCINES (2009)
Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines
P. Noel Barrett et al.
EXPERT REVIEW OF VACCINES (2009)
Efficacy of Injectable Trivalent Virosomal-Adjuvanted Inactivated Influenza Vaccine in Preventing Acute Otitis Media in Children With Recurrent Complicated or Noncomplicated Acute Otitis Media
Paola Marchisio et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2009)
Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels
Grazia Galli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients
Maurizio Setti et al.
VACCINE (2009)
Safe vaccination of children with a virosomal adjuvanted influenza vaccine
Valerie Kuenzi et al.
VACCINE (2009)
Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus
Gian Vincenzo Zuccotti et al.
VACCINE (2009)
Influenza vaccination in patients with cirrhosis and in liver transplant recipients
Giovanni B. Gaeta et al.
VACCINE (2009)
Eleven years of Inflexal® V-a virosomal adjuvanted influenza vaccine
Christian Herzog et al.
VACCINE (2009)
Recent advances with a virosomal hepatitis A vaccine
Patrick A. Bovier
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses
Benoit Baras et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2008)
Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy
Alessandra Vigano et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2008)
Safe administration of an inactivated virosomal adjuvanted influenza vaccine in asthmatic children with egg allergy
Susanna Esposito et al.
VACCINE (2008)
Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly
Iris de Bruijn et al.
VACCINE (2007)
Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma
Gianvincenzo Zuccotti et al.
VACCINE (2007)
Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3-14 years from the provider and societal perspectives
E. Navas et al.
VACCINE (2007)
Establishing the health and economic impact of influenza vaccination within the European Union 25 countries
James Ryan et al.
VACCINE (2006)
Inflexal® V -: The influenza vaccine with the lowest ovalbumin content
O. Kuersteiner et al.
VACCINE (2006)
Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3-14 years:: A prospective cohort study
L. Salleras et al.
VACCINE (2006)
T cell responses are better correlates of vaccine protection in the elderly
JE McElhaney et al.
JOURNAL OF IMMUNOLOGY (2006)
Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy
E Tanzi et al.
JOURNAL OF MEDICAL VIROLOGY (2006)
Antibody response to influenza vaccination in the elderly: A quantitative review
K Goodwin et al.
VACCINE (2006)
Clinical and economic impact of influenza vaccination on healthy children aged 2-5 years
S Esposito et al.
VACCINE (2006)
The impact of influenza on the health and health care utilisation of elderly people
DM Fleming et al.
VACCINE (2005)
The unmet need in the elderly: Designing new influenza vaccines for older adults
JE McElhaney
VACCINE (2005)
Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/duck/Singapore/97 (H5N3) vaccine: A potential priming strategy
I Stephenson et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Population-wide benefits of routine vaccination of children against influenza
D Weycker et al.
VACCINE (2005)
Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children
G Kanra et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2004)
Inactivated influenza virus vaccines in children
FL Ruben
CLINICAL INFECTIOUS DISEASES (2004)
Influenza virosomes enhance class I restricted CTL induction through CD4+T cell activation
R Schumacher et al.
VACCINE (2004)
Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly
BR Ruf et al.
INFECTION (2004)
Vaccination and autoimmune disease: what is the evidence?
DC Wraith et al.
LANCET (2003)
Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children - A randomized controlled trial
A Hoberman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines
KL Nichol
VACCINE (2003)
Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects
S Squarcione et al.
VACCINE (2003)
Immunogenicity and safety of an adjuvanted influenza vaccine in patients with decompensated cirrhosis
GB Gaeta et al.
VACCINE (2002)
Inflexal®V a trivalent virosome subunit influenza vaccine:: production
R Mischler et al.
VACCINE (2002)
Virosome-mediated delivery of protein antigens to dendritic cells
L Bungener et al.
VACCINE (2002)
Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly
DM Murasko et al.
EXPERIMENTAL GERONTOLOGY (2002)
Influenza vaccination of HIV-1-positive and HIV-1-negative former intravenous drug users
A Amendola et al.
JOURNAL OF MEDICAL VIROLOGY (2001)
Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza
KG Nicholson et al.
LANCET (2001)
Comparison of three different influenza vaccines in institutionalised elderly
V Baldo et al.
VACCINE (2001)
The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine
A Podda
VACCINE (2001)
Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly
F Pregliasco et al.
AGING CLINICAL AND EXPERIMENTAL RESEARCH (2001)
Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects
R Gasparini et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2001)
Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with cystic fibrosis
UB Schaad et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes
A Arkema et al.
VACCINE (2000)
Influenza and the rates of hospitalization for respiratory disease among infants and young children.
HS Izurieta et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children.
KM Neuzil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
